Innovations in NAFLD Care conferece co-chair Jeff Lazarus joins Roger Green, Louise Campbell and Jörn Schattenberg to review conference goals and ask whether the agenda and participants put forth a vision of an integrated NAFLD Care pathway.
Surfing NASH reviews the recently concluded 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This final conversation captures closing comments and thoughts on building the innovative program into the future.
Surfing NASH reviews the recently concluded 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation looks into the second day of the conference and the impact that the FDA ADCOM on obeticholic acid has on all of these issues discussed.
Surfing NASH reviews the recently concluded 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg. This conversation takes a deeper dive into what constitutes ‘preventative hepatology.’ The group teases out multiple concepts of what this could or should look like.
Surfing NASH reviews the recently concluded 2023 Innovations in NAFLD Care Workshop with conference founders and directors, Jeff Lazarus and Jörn Schattenberg.
Stephen Harrison speaks with Louise Campbell and Roger Green about the Nature Medicine published paper, Challenges and Opportunities in NASH Drug Development. This final conversation explores hepatocellular ballooning and the power of AI-assisted pathological assessment.
Stephen Harrison speaks with Louise Campbell and Roger Green about the Nature Medicine published paper, Challenges and Opportunities in NASH Drug Development. This conversation considers how to lower screen fail rates and the prospect of establishing guidelines for the biopsy reading process.
Stephen Harrison speaks with Louise Campbell and Roger Green about the Nature Medicine published paper, Challenges and Opportunities in NASH Drug Development. The group considers what exactly is moving the field rapidly forward. The focus of this conversation considers the future of AI-assisted digital pathology, NITs and screen fail rates.
Stephen Harrison speaks with Louise Campbell and Roger Green about challenges and opportunities in NASH drug development. The group dives deep into a range of topics including drugs with strong metabolic foundations, the state of histopathology, clinical trial design and screen fail rates, FDA ADCOM on obeticholic acid and much more.
Roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first major hepatology Congress to be held in person since the start of the pandemic (smaller, but very valuable, meetings like NASH-TAG, LiverCONNECT and Paris NASH have taken place with an in-person component, but the International Liver Congress and The Liver Meeting have not).
